<p><em>MITOLINE™算法推动首款针对线粒体载体的小分子药物开发，针对</em> <em>炎症代谢疾病</em> – 预计到 2030 年市场将超过 1200 亿美元</p>
<p>以色列内夫雅拉克，2026 年 2 月 12 日（GLOBE NEWSWIRE）-- N2OFF, Inc.（纳斯达克：NITO）（“N2OFF” 和 “公司”），一家药物发现公司，同时基于 RTB（Ready to Build）商业模式投资于太阳能资产，最近宣布其全资子公司 MitoCareX Bio Ltd.（“MitoCareX Bio”），一家专注于开发针对人类线粒体载体的小分子药物的生物技术公司，已显示出初步的体外数据，证明其专有发现平台能够抑制人类免疫细胞中的促炎反应。</p>
<p>利用 MITOLINE™衍生的模型，MitoCareX 组建了一个专注的小分子候选药物库，目前正在一系列专有的体外检测中进行评估，这些检测旨在捕捉线粒体功能、炎症信号和代谢读数。新报告的体外数据表明，所选候选药物能够降低人类免疫细胞中的关键炎症标志物，为 MitoCareX Bio 提供了初步证据，表明线粒体载体调节可以在与人类相关的系统中提供抗炎益处。这些结果支持在多种炎症代谢疾病指征中进一步进行体内验证和先导优化，包括与代谢综合症相关的疾病。</p>
<p>炎症及炎症代谢疾病代表了全球制药行业中增长最快的治疗领域之一，预计抗炎药物的市场规模将从 2024 年的约 1220 亿美元增长到 2034 年的近 2750 亿美元（年均增长率约 8.4%）。在这一领域，仅小分子免疫调节剂的市场预计将从 2025 年的约 1880 亿美元增长到 2035 年的超过 3500 亿美元（年均增长率约 6.5%），突显出对口服、靶向抗炎疗法的强劲和持续需求。代谢疾病治疗，包括糖尿病及相关综合症等关键炎症代谢疾病，预计在 2024 年约为 770 亿美元，并预计到 2030 年将超过 1200 亿美元。</p>
<p>MitoCareX 的尖端 MITOLINE™算法克服了线粒体药物发现中的一个关键瓶颈：大多数人类线粒体载体缺乏已解决的三维结构。MITOLINE™应用先进的序列分析，能够可靠地生成线粒体载体蛋白的三维比较模型，使 MitoCareX 能够表征其虚拟筛选活动中的底物转运结合位点。该平台支持快速识别与肿瘤学、自身免疫和代谢 - 炎症疾病相关的线粒体载体的创新小分子骨架。</p>
<p>MitoCareX Bio 计划将其最有前景的线粒体靶向抗炎候选药物推进至临床前研究，同时继续扩大基于 MITOLINE™的发现引擎，涵盖更多线粒体载体靶点。</p>
<p><strong>关于 N2OFF Inc:</strong></p>
<p>N2OFF 拥有 MitoCareX Bio Ltd.的 100% 股份，这是一家通过线粒体 SLC25 蛋白家族针对癌症治疗和其他疾病的药物发现公司。此外，N2OFF 采用了一种投资策略，专注于利用 RTB（Ready to Build）商业模式的欧洲可再生能源资产。该公司目前是三个欧盟国家四个太阳能项目的主要投资者，所有项目均由 Solterra Renewable Energy Ltd.引入，后者是 Solterra Energy Ltd.的全资子公司。</p>
<p>N2OFF 还控制着约 98% 的 Save Foods Ltd.，这是一家以色列公司，专注于减少水果和蔬菜中病原体污染的后收获处理技术。</p>
<p>欲了解更多信息，请访问 www.n2off.com。</p>
<p><strong>前瞻性声明：</strong></p>
<p>本新闻稿包含根据 1995 年《私人证券诉讼改革法案》和其他联邦证券法的 “安全港” 条款的前瞻性声明。诸如 “预计”、“预期”、“打算”、“计划”、“相信”、“寻求”、“估计” 等词语及其类似表达或变体旨在识别前瞻性声明。例如，当公司讨论全球抗炎药市场、小分子免疫调节剂市场和全球代谢性疾病治疗市场的预期增长，以及 MitoCareX Bio 计划如何推进其最有前景的线粒体靶向抗炎候选药物进入临床前研究，同时继续扩大基于 MITOLINE™的发现引擎以涵盖更多线粒体载体靶点时，便使用了前瞻性声明。由于前瞻性声明涉及尚未发生的事项，因此这些声明本质上受到已知和未知的风险、不确定性及其他因素的影响，这些因素可能导致 N2OFF 及其子公司的实际结果、表现或成就与前瞻性声明所表达或暗示的任何未来结果、表现或成就存在重大差异。可能导致实际结果、表现或成就与这些前瞻性声明中预期的结果存在重大差异的重要因素包括但不限于我们的市场和其他条件、亏损历史以及为资助我们的运营而需要额外资本的需求，以及我们无法以可接受的条款获得额外资本，或根本无法获得；现金流的不确定性和无法满足营运资金需求；我们的临床前研究、临床试验和其他产品候选开发工作的启动、时间、进展和结果；我们将产品候选推进至临床试验的能力或成功完成临床前研究或临床试验的能力；我们获得产品候选的监管批准的能力，以及其他监管申请和批准的时间；我们产品候选的临床开发、商业化和市场接受度；我们建立和维持战略合作伙伴关系及其他企业合作的能力；我们业务和产品候选的商业模式和战略计划的实施；我们能够建立和维持的知识产权保护范围，以及我们在不侵犯他人知识产权的情况下运营业务的能力；竞争公司、技术及我们的行业；未能满足纳斯达克资本市场持续上市要求的风险；以及以色列的政治和安全形势对我们业务的影响的声明。有关这些风险、不确定性和其他因素的更多信息，随时可在 N2OFF 于 2025 年 3 月 31 日向证券交易委员会（“SEC”）提交的 10-K 表格年度报告的 “风险因素” 部分及其他向 SEC 提交的公开报告中找到。除法律另有要求外，我们不承担公开发布任何修订前瞻性声明的义务，以反映本日期后的事件或情况，或反映意外事件的发生。提供网站的引用和链接仅为方便，网站上包含的信息不被纳入本新闻稿的引用中。我们对第三方网站的内容不承担任何责任。</p>
<p>投资者关系联系人：</p>
<p>Michal Efraty</p>
<p>michal@efraty.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU16WTJPU00zTkRJek16STBJelV3TURBMU16WTJOZz09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU16WTJPU00zTkRJek16STBJelV3TURBMU16WTJOZz09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmNkNWY0MmItNmRkYS00OTM5LWE3YjktYmU5MzIxN2U0MjEzLTUwMDA1MzY2Ni0yMDI2LTAyLTEyLWVu/tiny/N2OFF-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmNkNWY0MmItNmRkYS00OTM5LWE3YjktYmU5MzIxN2U0MjEzLTUwMDA1MzY2Ni0yMDI2LTAyLTEyLWVu/tiny/N2OFF-Inc-.png"/></p>

NITO

动态生物技术与基因组 ETF - Invesco

2 倍做多纳斯达克生物技术 ETF - ProShares

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

NXTS

<p>MitoCareX Bio，N2OFF, Inc. 的子公司，报告了成功的体外结果，显示其 MITOLINE™ 驱动的小分子能够抑制人类免疫细胞中的促炎反应。这一突破针对炎症代谢疾病，预计到 2030 年市场将超过 1200 亿美元。该公司计划将其有前景的候选药物推进到临床前研究，同时扩展其发现引擎。抗炎药物市场预计将显著增长，突显了该治疗领域对靶向疗法的需求</p>

<p><em>MITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for</em> <em>Inflammatory Metabolic Diseases</em> – A Market Projected to Exceed $120 billion by 2030</p>
<div class="lb-trans"><p><em>MITOLINE™算法推动首款针对线粒体载体的小分子药物开发，针对</em> <em>炎症代谢疾病</em> – 预计到 2030 年市场将超过 1200 亿美元</p>
</div><p>Neve Yarak, Israel, Feb. 12, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, recently announced that MitoCareX Bio Ltd. (“MitoCareX Bio”), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary, has shown preliminary in vitro data demonstrating inhibition of pro‑inflammatory responses in human immune cells using its proprietary discovery platform.</p>
<div class="lb-trans"><p>以色列内夫雅拉克，2026 年 2 月 12 日（GLOBE NEWSWIRE）-- N2OFF, Inc.（纳斯达克：NITO）（“N2OFF” 和 “公司”），一家药物发现公司，同时基于 RTB（Ready to Build）商业模式投资于太阳能资产，最近宣布其全资子公司 MitoCareX Bio Ltd.（“MitoCareX Bio”），一家专注于开发针对人类线粒体载体的小分子药物的生物技术公司，已显示出初步的体外数据，证明其专有发现平台能够抑制人类免疫细胞中的促炎反应。</p>
</div><p>Using MITOLINE™‑derived models, MitoCareX has assembled a focused library of small‑molecule candidates that is now being evaluated in a suite of proprietary in-vitro assays designed to capture mitochondrial function, inflammatory signalling, and metabolic readouts. The newly reported in vitro data show that selected candidates reduce key inflammatory markers in human immune cells, providing MitoCareX Bio with an initial line of evidence that mitochondrial carrier modulation can deliver anti‑inflammatory benefit in human‑relevant systems. These results support further in vivo validation and lead optimization across multiple inflammatory metabolic disease indications including diseases related to the metabolic syndrome.</p>
<div class="lb-trans"><p>利用 MITOLINE™衍生的模型，MitoCareX 组建了一个专注的小分子候选药物库，目前正在一系列专有的体外检测中进行评估，这些检测旨在捕捉线粒体功能、炎症信号和代谢读数。新报告的体外数据表明，所选候选药物能够降低人类免疫细胞中的关键炎症标志物，为 MitoCareX Bio 提供了初步证据，表明线粒体载体调节可以在与人类相关的系统中提供抗炎益处。这些结果支持在多种炎症代谢疾病指征中进一步进行体内验证和先导优化，包括与代谢综合症相关的疾病。</p>
</div><p>Inflammatory and inflammatory metabolic diseases represent one of the fastest‑growing therapeutic areas in global pharma, with anti‑inflammatory drugs expected to grow from approximately $122 billion in 2024 to nearly $275 billion by 2034 (CAGR ~8.4%). Within this landscape, small‑molecule immunomodulators alone are projected to expand from around $188 billion in 2025 to more than $350 billion by 2035 (CAGR ~6.5%), underscoring strong and sustained demand for oral, targeted anti‑inflammatory therapies. Metabolic disorder therapeutics, which include key inflammatory metabolic diseases such as diabetes and related syndromes, are estimated around $77 billion in 2024 and forecast to surpass $120 billion by 2030.</p>
<div class="lb-trans"><p>炎症及炎症代谢疾病代表了全球制药行业中增长最快的治疗领域之一，预计抗炎药物的市场规模将从 2024 年的约 1220 亿美元增长到 2034 年的近 2750 亿美元（年均增长率约 8.4%）。在这一领域，仅小分子免疫调节剂的市场预计将从 2025 年的约 1880 亿美元增长到 2035 年的超过 3500 亿美元（年均增长率约 6.5%），突显出对口服、靶向抗炎疗法的强劲和持续需求。代谢疾病治疗，包括糖尿病及相关综合症等关键炎症代谢疾病，预计在 2024 年约为 770 亿美元，并预计到 2030 年将超过 1200 亿美元。</p>
</div><p>MitoCareX’s cutting‑edge MITOLINE™ algorithm overcomes a critical bottleneck in mitochondrial drug discovery: the lack of solved 3D structures for most human mitochondrial carriers. MITOLINE™ applies advanced sequence based analyses to enable reliable 3D comparative models of mitochondrial carrier proteins, allowing MitoCareX to characterize substrate translocation binding sites for its virtual screening campaigns. This platform supports rapid identification of novel small‑molecule scaffolds that engage mitochondrial carriers implicated in oncology, autoimmune, and metabolic‑inflammatory diseases.</p>
<div class="lb-trans"><p>MitoCareX 的尖端 MITOLINE™算法克服了线粒体药物发现中的一个关键瓶颈：大多数人类线粒体载体缺乏已解决的三维结构。MITOLINE™应用先进的序列分析，能够可靠地生成线粒体载体蛋白的三维比较模型，使 MitoCareX 能够表征其虚拟筛选活动中的底物转运结合位点。该平台支持快速识别与肿瘤学、自身免疫和代谢 - 炎症疾病相关的线粒体载体的创新小分子骨架。</p>
</div><p>MitoCareX Bio plans to advance its most promising mitochondrial‑targeted anti‑inflammatory candidates toward pre-clinical studies, while continuing to broaden the MITOLINE™‑powered discovery engine across additional mitochondrial carrier targets.</p>
<div class="lb-trans"><p>MitoCareX Bio 计划将其最有前景的线粒体靶向抗炎候选药物推进至临床前研究，同时继续扩大基于 MITOLINE™的发现引擎，涵盖更多线粒体载体靶点。</p>
</div><p><strong>About N2OFF Inc:</strong></p>
<div class="lb-trans"><p><strong>关于 N2OFF Inc:</strong></p>
</div><p>N2OFF owns 100% of MitoCareX Bio Ltd, a drug discovery company engaged in targeting cancer therapeutics and other diseases through the mitochondrial SLC25 protein family. Additionally, N2OFF adopted an investment strategy focused on European renewable energy assets utilizing a RTB (Ready to Build) business model. The Company is currently the lead investor in four solar projects across three European Union countries, all introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd.</p>
<div class="lb-trans"><p>N2OFF 拥有 MitoCareX Bio Ltd.的 100% 股份，这是一家通过线粒体 SLC25 蛋白家族针对癌症治疗和其他疾病的药物发现公司。此外，N2OFF 采用了一种投资策略，专注于利用 RTB（Ready to Build）商业模式的欧洲可再生能源资产。该公司目前是三个欧盟国家四个太阳能项目的主要投资者，所有项目均由 Solterra Renewable Energy Ltd.引入，后者是 Solterra Energy Ltd.的全资子公司。</p>
</div><p>N2OFF also controls approximately 98% of Save Foods Ltd., an Israeli company focused on post-harvest treatment technologies designed to reduce pathogen contamination in fruits and vegetables.</p>
<div class="lb-trans"><p>N2OFF 还控制着约 98% 的 Save Foods Ltd.，这是一家以色列公司，专注于减少水果和蔬菜中病原体污染的后收获处理技术。</p>
</div><p>For more information, please visit www.n2off.com.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 www.n2off.com。</p>
</div><p><strong>Forward-looking Statements:</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明：</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expected growth of global anti-inflammatory drugs market, the small molecule immunomodulators market and the global metabolic disorder therapeutics market and how MitoCareX Bio plans to advance its most promising mitochondrial‑targeted anti‑inflammatory candidates toward pre-clinical studies, while continuing to broaden the MITOLINE™‑powered discovery engine across additional mitochondrial carrier targets. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause N2OFF’s and its subsidiaries’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of Nasdaq Capital Market; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of N2OFF’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 31, 2025 and other public reports filed with the SEC. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. We are not responsible for the contents of third-party websites.</p>
<div class="lb-trans"><p>本新闻稿包含根据 1995 年《私人证券诉讼改革法案》和其他联邦证券法的 “安全港” 条款的前瞻性声明。诸如 “预计”、“预期”、“打算”、“计划”、“相信”、“寻求”、“估计” 等词语及其类似表达或变体旨在识别前瞻性声明。例如，当公司讨论全球抗炎药市场、小分子免疫调节剂市场和全球代谢性疾病治疗市场的预期增长，以及 MitoCareX Bio 计划如何推进其最有前景的线粒体靶向抗炎候选药物进入临床前研究，同时继续扩大基于 MITOLINE™的发现引擎以涵盖更多线粒体载体靶点时，便使用了前瞻性声明。由于前瞻性声明涉及尚未发生的事项，因此这些声明本质上受到已知和未知的风险、不确定性及其他因素的影响，这些因素可能导致 N2OFF 及其子公司的实际结果、表现或成就与前瞻性声明所表达或暗示的任何未来结果、表现或成就存在重大差异。可能导致实际结果、表现或成就与这些前瞻性声明中预期的结果存在重大差异的重要因素包括但不限于我们的市场和其他条件、亏损历史以及为资助我们的运营而需要额外资本的需求，以及我们无法以可接受的条款获得额外资本，或根本无法获得；现金流的不确定性和无法满足营运资金需求；我们的临床前研究、临床试验和其他产品候选开发工作的启动、时间、进展和结果；我们将产品候选推进至临床试验的能力或成功完成临床前研究或临床试验的能力；我们获得产品候选的监管批准的能力，以及其他监管申请和批准的时间；我们产品候选的临床开发、商业化和市场接受度；我们建立和维持战略合作伙伴关系及其他企业合作的能力；我们业务和产品候选的商业模式和战略计划的实施；我们能够建立和维持的知识产权保护范围，以及我们在不侵犯他人知识产权的情况下运营业务的能力；竞争公司、技术及我们的行业；未能满足纳斯达克资本市场持续上市要求的风险；以及以色列的政治和安全形势对我们业务的影响的声明。有关这些风险、不确定性和其他因素的更多信息，随时可在 N2OFF 于 2025 年 3 月 31 日向证券交易委员会（“SEC”）提交的 10-K 表格年度报告的 “风险因素” 部分及其他向 SEC 提交的公开报告中找到。除法律另有要求外，我们不承担公开发布任何修订前瞻性声明的义务，以反映本日期后的事件或情况，或反映意外事件的发生。提供网站的引用和链接仅为方便，网站上包含的信息不被纳入本新闻稿的引用中。我们对第三方网站的内容不承担任何责任。</p>
</div><p>Investor Relations Contact:</p>
<div class="lb-trans"><p>投资者关系联系人：</p>
</div><p>Michal Efraty</p>
<div class="lb-trans"><p>Michal Efraty</p>
</div><p>michal@efraty.com</p>
<div class="lb-trans"><p>michal@efraty.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU16WTJPU00zTkRJek16STBJelV3TURBMU16WTJOZz09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTY1MzY2OSM3NDIzMzI0IzUwMDA1MzY2Ng=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmNkNWY0MmItNmRkYS00OTM5LWE3YjktYmU5MzIxN2U0MjEzLTUwMDA1MzY2Ni0yMDI2LTAyLTEyLWVu/tiny/N2OFF-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MmNkNWY0MmItNmRkYS00OTM5LWE3YjktYmU5MzIxN2U0MjEzLTUwMDA1MzY2Ni0yMDI2LTAyLTEyLWVu/tiny/N2OFF-Inc-.png"/></p>

MitoCareX Bio Reports Successful Results in Vitro: MITOLINE™-Powered Small Molecules Show Anti-Inflammatory Potential for Metabolic Syndrome-Related Diseases | NITO Stock News

StockTitan

N2OFF

Nexentis Tech

MitoCareX Bio 报告体外实验成功结果：由 MITOLINE™驱动的小分子显示出对代谢综合症相关疾病的抗炎潜力 | NITO 股票新闻